The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient.
A-L-B  (I).

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

A composition for use in vascular relaxation, wherein the composition includes at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an ethyl ester of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or an amino acid salt of EPA or DHA. The anthocyanin component is cyanidin-3-galactoside, or delphinidin-3-arabinoside. Further, the omega-3 fatty acid salt has an organic counter ion which is lysine, arginine, ornithine and mixtures of the same. The composition further includes cyanidin-3-galactoside. The composition further includes fruits extracts or cereals extracts. A method for treating a disease with the composition.

A composition for use in vascular relaxation, wherein the composition includes at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an ethyl ester of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or an amino acid salt of EPA or DHA. The anthocyanin component is cyanidin-3-galactoside, or delphinidin-3-arabinoside. Further, the omega-3 fatty acid salt has an organic counter ion which is lysine, arginine, ornithine and mixtures of the same. The composition further includes cyanidin-3-galactoside. The composition further includes fruits extracts or cereals extracts. A method for treating a disease with the composition.

A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The elastomeric adhesive composition may be a hydro-colloid-adhesive composition comprising, hydrocolloid and elastomer. The dressing composition releases nitric oxide, which may have beneficial effects, when used on wounds or moist skin, with a substantially constant release rate over a long period of time. A dressing including a layer of the dressing composition has a backing layer and may have a release liner removably attached to the skin-contacting surface of the dressing layer.

Described herein is a cyclodextrin containing polymer conjugate.

The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-γ in a subject.

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

The invention relates to processes for preparing benzoprostacyclin analogues and intermediates prepared from the process, and the benzoprostacyclin analogues prepared therefrom. The invention also relates to cyclopentenone intermediates in racemic or optically active form.

In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.